Skip to content

Exhaled nitric oxide levels in cardiovascular patients and its role in predicting adverse events in atrial fibrillation

Exhaled nitric oxide levels in cardiovascular patients and its role in predicting adverse events in atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052059
Enrollment
Unknown
Registered
2021-10-16
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Sinus rhythm group:No
Atrial fibrillation group:No

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients hospitalized in the First Affiliated Hospital of Wenzhou Medical University; 2. Patients underwent at least two electrocardiogram examinations; 3. The rhythm types were determined by two different doctors' interpretation.

Exclusion criteria

Exclusion criteria: 1. Patients with other types of arrhythmias eventually determined by electrocardiogram or electrophysiological examination; 2. Patients with acute and chronic heart failure (HYHA III-IV) require hemodialysis or ventilator therapy; 3. Suffering from lung infection, bronchial asthma, COPD and other lung diseases; 4. Nitrates or sodium nitroprusside drugs are being used; patients with pulmonary hypertension; 5. Patients with rheumatic heart disease; 6. Patients with acute myocardial infarction KILLIP grade 3-4 requiring ventilator support or intra-aortic balloon dilation; 7. Patients with hemodynamic instability; 8. Patients needing emergency treatment due to shock of various causes; 9. Patients with serious complications after radiofrequency ablation of atrial fibrillation, such as injury of the Hibachi tract, degree II or III atrioventricular block, or cardiac perforation; 10. Persons who are conducting other clinical trials.

Design outcomes

Primary

MeasureTime frame
FeNO(fractional exhaled nitric oxide);

Secondary

MeasureTime frame
Cardiac uhrasonography;Blood pressure;Hepatic function;Fasting blood glucose;Blood fat;Hs-CRP(hypersensitive-C-reactive-protein);BNP(brain natriuretic peptide);ECG(electrocardiogram);Pulmonary function;Thyroid function;Procalcitonin;Hyaluronic acid;Collagen TV;Collagen III;Laminin;NOS(nitric oxide synthase);Renal function;

Countries

China

Contacts

Public ContactQu Xiang

The First Affiliated Hospital of Wenzhou Medical University

cookie774@163.com+86 13616633181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026